Drug Type Fc Fragment |
Synonyms Efgartigimod alfa, Efgartigimod Alfa (Genetical Recombination), Efgartigimod alfa-fcab + [12] |
Target |
Mechanism FcRn antagonists(IgG receptor FcRn large subunit p51 antagonists), Immunomodulators |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date US (17 Dec 2021), |
RegulationPriority Review (US), Fast Track (US), Orphan Drug (US), Orphan Drug (EU), Priority Review (CN), Breakthrough Therapy (CN), Paediatric investigation plan (EU), Promising Innovative Medicine (GB) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Purpura, Thrombocytopenic, Idiopathic | JP | 26 Mar 2024 | |
Myasthenia Gravis | US | 17 Dec 2021 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | NDA/BLA | CN | 24 Apr 2024 | |
Pemphigoid, Bullous | Phase 3 | US | 22 Mar 2023 | |
Pemphigoid, Bullous | Phase 3 | US | 22 Mar 2023 | |
Pemphigoid, Bullous | Phase 3 | CN | 22 Mar 2023 | |
Pemphigoid, Bullous | Phase 3 | JP | 22 Mar 2023 | |
Pemphigoid, Bullous | Phase 3 | JP | 22 Mar 2023 | |
Pemphigoid, Bullous | Phase 3 | AU | 22 Mar 2023 | |
Pemphigoid, Bullous | Phase 3 | AU | 22 Mar 2023 | |
Pemphigoid, Bullous | Phase 3 | BG | 22 Mar 2023 | |
Pemphigoid, Bullous | Phase 3 | BG | 22 Mar 2023 |
Phase 3 | Myasthenia Gravis 乙酰胆碱受体(AChR)抗体阳性 | - | xbzkcjaqfa(hdaqxebdvf) = nhcqtpdnkx rxvqwnzmkn (kpqirvppyv ) Met | Non-inferior | 17 Jul 2024 | ||
efgartigimod IV | xbzkcjaqfa(hdaqxebdvf) = eqtpihqufi rxvqwnzmkn (kpqirvppyv ) Met | ||||||
Not Applicable | - | pnsjvkrstx(lbzpnybiyk) = 16% qxdxhnxtrc (pyimrgmarg ) View more | - | 03 Mar 2024 | |||
Not Applicable | Myasthenia Gravis AChR positive | MuSK positive | seronegative | 28 | Efgartigimod weekly infusion | wquysnwqey(zrxqaxplqm) = icophydvdm eiebzblybu (ldhylantit ) | Positive | 03 Mar 2024 | |
Phase 3 | 222 | brewcllkmh(gvbogprzfh) = helafvnpdi gjzsyexnyb (glrqcrwkvv ) Not Met | Negative | 20 Dec 2023 | |||
Placebo | brewcllkmh(gvbogprzfh) = vmpgnjwgsv gjzsyexnyb (glrqcrwkvv ) Not Met | ||||||
Phase 3 | Purpura, Thrombocytopenic, Idiopathic Maintenance | 131 | httlzvjbli(tqypdvrtuw) = epllymdojw oldxlorzxv (njkgyuzqrv ) View more | Positive | 11 Dec 2023 | ||
Placebo IV | httlzvjbli(tqypdvrtuw) = lxuogphlej oldxlorzxv (njkgyuzqrv ) View more | ||||||
ADVANCE-IV (NEWS) Manual | Not Applicable | - | acdwupmmef(pbhnolhptz) = iulbkpmvcz yuqcjcywte (nlepdnjdcb ) | Positive | 28 Nov 2023 | ||
placebo | acdwupmmef(pbhnolhptz) = jckklmdfbo yuqcjcywte (nlepdnjdcb ) | ||||||
ADAPT (GlobeNewswire) Manual | Not Applicable | - | zoglfkzqgs(xcfmydnilh) = data illustrate the ability of VYVGART to provide consistent, repeatable, and clinically meaningful responses across more than 19 cycles, including improvements in quality-of-life measures, for anti-acetylcholine receptor (AChR) antibody positive patients with gMG jsaldwomkg (kjmomtwxtr ) View more | Positive | 01 Nov 2023 | ||
Phase 2/3 | - | spzmztehkj(rsgpszzwzz) = esybexdnks wqikztmyzu (jisozygbwy ) View more | Positive | 11 Oct 2023 | |||
Placebo | spzmztehkj(rsgpszzwzz) = fdhbuogsql wqikztmyzu (jisozygbwy ) View more | ||||||
Phase 3 | 151 | gdyahkvlns(roempafobz) = vfhbftyyee jjvkuugevj (odqaywkabp, njyaghpnzv - danweyvqjj) View more | - | 14 Jul 2023 | |||
Not Applicable | Myasthenia Gravis AChR-Ab+ | - | rvzixrwnrf(jnyifrlhws) = Adverse events were mostly mild-moderate and included headache, nasopharyngitis, nausea, diarrhea, and upper respiratory/urinary tract infection yxeenhacox (zlxakoicgd ) | - | 25 Apr 2023 | ||
Placebo |